TrialAlzheimer's research & therapy2018

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).

Stephen Salloway et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.